Last updated: July 31, 2026
Ethotoin is a legacy hydantoin anticonvulsant with no active clinical-development program, no meaningful new-trial activity, and limited commercial relevance. The drug’s U.S. product history is associated with Peganone, an oral prescription product formerly used for seizure disorders. Its basic composition, therapeutic use, and conventional tablet formulation are long outside the normal patent-exclusivity period. Current commercial prospects are limited to small legacy markets, hospital procurement, and potential supply from specialized manufacturers rather than branded pharmaceutical growth.
What is the current clinical-trial status of ethotoin?
Ethotoin has no identifiable active interventional clinical-trial program in the major public trial registries. ClinicalTrials.gov lists historical anticonvulsant research involving older hydantoins, but ethotoin does not have a current development pipeline comparable with newer antiseizure medicines such as cenobamate, brivaracetam, lacosamide, or perampanel (ClinicalTrials.gov, 2024).
| Clinical-development category |
Ethotoin status |
| Active Phase 1 trials |
None identified |
| Active Phase 2 trials |
None identified |
| Active Phase 3 trials |
None identified |
| Registration-enabling studies |
None identified |
| Pediatric development program |
None identified |
| New formulation program |
None identified |
| Orphan-drug development |
None identified |
| Biosimilar program |
Not applicable |
| Generic-equivalence development |
Possible only as a commercial product exercise |
Ethotoin was developed before the modern clinical-trial framework used for most current antiseizure drugs. Its clinical evidence base consists mainly of historical studies, product labeling, and postmarketing experience rather than contemporary randomized development programs.
What medical use does ethotoin have?
Ethotoin is a hydantoin anticonvulsant historically used for the control of seizures. Its pharmacologic class is related to phenytoin and fosphenytoin. The drug was used primarily in epilepsy, including seizure types for which a hydantoin mechanism was considered clinically appropriate.
Its clinical use declined as physicians adopted drugs with better-established dosing convenience, broader seizure coverage, improved interaction profiles, and more predictable tolerability. Current epilepsy treatment guidelines generally prioritize newer agents or better-established older drugs over ethotoin.
Is ethotoin still approved and marketed by the FDA?
Ethotoin has no active U.S. commercial position comparable with currently marketed antiseizure medicines. Peganone, historically associated with ethotoin, is generally treated as a discontinued or commercially inactive product in U.S. drug databases.
FDA discontinuation status does not by itself establish that a drug was withdrawn for safety or efficacy reasons. FDA records distinguish commercial discontinuation from withdrawal for safety or effectiveness concerns (U.S. Food and Drug Administration, 2024a).
| FDA and U.S. market issue |
Assessment |
| Active branded U.S. product |
No meaningful current availability identified |
| Historical brand |
Peganone |
| Active NDA commercial program |
No active commercial program identified |
| Current prescribing market |
Very limited or absent |
| FDA safety withdrawal finding |
No basis to classify commercial discontinuation as a safety withdrawal |
| Current guideline position |
Not a leading therapy for epilepsy |
| U.S. generic competition |
No significant active market identified |
Ethotoin may remain present in historical formularies, legacy references, or international regulatory records. Product availability can differ by country and may depend on a local manufacturer, importer, or hospital procurement channel.
What patents protect ethotoin?
No commercially relevant active patent estate is apparent for ethotoin’s basic active ingredient. Ethotoin was introduced decades ago, placing composition-of-matter protection well beyond the ordinary 20-year patent term under modern patent law.
| Patent category |
Current commercial significance |
| Ethotoin composition patent |
Expired |
| Basic anticonvulsant use patent |
Expired or not commercially relevant |
| Original tablet formulation patent |
Expired |
| Manufacturing-process patent |
Expired or unlikely to block routine production |
| Extended-release formulation patent |
No active estate identified |
| Combination-product patent |
No meaningful estate identified |
| Device or delivery-system patent |
Not applicable |
| Pediatric exclusivity |
None identified |
| New chemical entity exclusivity |
Expired decades ago |
The absence of a current patent barrier does not guarantee supply. A manufacturer still must address active-pharmaceutical-ingredient sourcing, formulation quality, stability, analytical validation, regulatory filings, and commercial demand.
Does ethotoin have Orange Book protection?
Ethotoin has no meaningful current Orange Book exclusivity position identified. The Orange Book records approved drug products and certain patent and exclusivity information, but an old product with no active commercial sponsor may have no operative patent listing relevant to a new entrant (U.S. Food and Drug Administration, 2024b).
A new manufacturer seeking U.S. approval would likely rely on an abbreviated or other applicable regulatory pathway based on the reference product and available FDA requirements. A Paragraph IV challenge would have little strategic value unless an active listed patent existed. No material Paragraph IV litigation involving ethotoin has been identified.
When did ethotoin lose exclusivity?
Ethotoin lost practical exclusivity many years ago. The drug predates the modern Hatch-Waxman framework, and any original composition protection would have expired long before the current market period.
| Exclusivity type |
Expected status |
| Composition-of-matter patent |
Expired |
| Regulatory data exclusivity |
Expired |
| Orphan exclusivity |
Not identified |
| Pediatric exclusivity |
Not identified |
| Market exclusivity under a modern NDA |
Expired |
| Patent-term extension |
Not relevant to the historical product |
| Current regulatory exclusivity |
None identified |
The commercial issue is therefore not loss of exclusivity. It is the absence of a sufficiently large market to support development, manufacturing, distribution, and pharmacovigilance costs.
What formulations of ethotoin are protected?
The historical commercial product was an oral tablet. No active patent protection has been identified for a clinically meaningful ethotoin formulation.
Potential product categories include:
- Immediate-release tablets
- Different tablet strengths
- Hospital or specialty-pharmacy supply
- Compounded oral preparations where legally permitted
- Potential liquid formulations for patients unable to swallow tablets
A new liquid, modified-release, or pediatric formulation could theoretically create a new patent position if it met novelty and non-obviousness standards. That opportunity would be constrained by low demand and the availability of alternative antiseizure treatments.
Is there ethotoin patent litigation or a settlement agreement?
No significant current patent litigation, Paragraph IV settlement, or licensing dispute involving ethotoin has been identified in the public record.
| Legal issue |
Current assessment |
| ANDA litigation |
None identified |
| Paragraph IV certification dispute |
None identified |
| Patent settlement |
None identified |
| Licensing transaction |
No material recent transaction identified |
| Manufacturing dispute |
None identified |
| Product-liability activity affecting market entry |
No major current matter identified |
The absence of litigation reflects the drug’s limited commercial value and lack of an active branded patent estate.
How large is the ethotoin market?
Ethotoin does not represent a material global pharmaceutical market. Public-company disclosures and standard commercial-market reports generally do not separate ethotoin into a standalone revenue category. Sales, if any, are likely recorded within broader legacy anticonvulsant, hospital, or specialty-product categories.
| Market segment |
Outlook |
| U.S. branded sales |
Negligible or unavailable |
| U.S. retail generic sales |
Very limited |
| Hospital demand |
Small and procurement-dependent |
| International sales |
Country-specific and uncertain |
| Specialty pharmacy |
Limited |
| New branded development |
Commercially unattractive |
| API opportunity |
Niche, dependent on confirmed demand |
A conventional top-down market forecast would overstate the opportunity because prescription volume is likely too low for reliable public measurement. The more useful approach is a scenario model based on product availability.
Ethotoin revenue projection
The following projection is an analytical market scenario, not reported company revenue. It assumes that ethotoin remains a niche legacy product without new clinical positioning.
| Scenario |
2025 estimated global sales |
2030 estimated global sales |
Main driver |
| Base case |
Below $5 million |
Below $5 million |
Stable but shrinking legacy demand |
| Downside case |
Below $2 million |
Near zero |
Product discontinuation and substitution |
| Upside case |
$5 million-$15 million |
$5 million-$20 million |
Re-entry by a niche supplier or sustained international demand |
The upside case would require a manufacturer to confirm a dependable API source, obtain or maintain country-specific approvals, and secure predictable purchasing contracts. It would not depend on patent exclusivity.
What generic entry risks exist for ethotoin?
Generic entry risk is technically high but commercially weak. Any active ingredient and basic tablet patent barriers are expired, so a capable manufacturer could potentially enter without facing a blocking patent portfolio. The principal obstacles are regulatory and economic.
Manufacturing and regulatory barriers
A prospective supplier would need to address:
- API availability and qualified suppliers.
- Good manufacturing practice compliance.
- Bioequivalence or other applicable approval requirements.
- Stability data and packaging.
- Control of impurities and degradation products.
- Reliable distribution to a small patient population.
- Pharmacovigilance and shortage-management obligations.
The low-volume nature of the product can make manufacturing less attractive. Small batches raise unit costs, while low prescription volume limits the ability to recover regulatory and quality-system expenses.
How does ethotoin compare with competing anticonvulsants?
Ethotoin competes indirectly with generic phenytoin, fosphenytoin, carbamazepine, valproate, phenobarbital, levetiracetam, lamotrigine, and newer antiseizure therapies.
| Drug |
Commercial position |
Main advantage over ethotoin |
| Phenytoin |
Established generic market |
Greater clinical familiarity and availability |
| Fosphenytoin |
Hospital and acute-care use |
Injectable prodrug and established acute-use role |
| Levetiracetam |
Large generic market |
Broad use and simpler clinical positioning |
| Lamotrigine |
Established generic market |
Use across multiple seizure and mood-related indications |
| Valproate |
Large generic market |
Broad-spectrum activity |
| Carbamazepine |
Established generic market |
Long clinical history and multiple formulations |
| Cenobamate |
Branded innovative market |
Newer mechanism and refractory-epilepsy positioning |
Ethotoin lacks a clear clinical or economic advantage against these alternatives. Its most defensible niche would involve a patient already controlled on the drug and unable to transition safely, but that niche is too small to support a conventional branded strategy.
Is there biosimilar risk for ethotoin?
Biosimilar risk does not apply. Ethotoin is a small-molecule drug, not a biologic. Competitive risk comes from generic small-molecule products, therapeutic substitution, pharmacy-level formulary decisions, and discontinuation of legacy supply.
What is the investment outlook for ethotoin?
Ethotoin has low attractiveness for conventional pharmaceutical investment. The patent estate does not provide a protected pricing period, the clinical pipeline is inactive, and the addressable market is small.
Potential value may exist in a narrowly defined supply transaction involving:
- A confirmed shortage or discontinuation event.
- A hospital system with recurring demand.
- A regional regulatory approval.
- A manufacturer with existing hydantoin production capacity.
- A portfolio acquisition where ethotoin is bundled with other legacy products.
A standalone branded relaunch would face weak pricing power and substantial substitution risk.
Key Takeaways
- Ethotoin has no active clinical-trial program or modern development pipeline.
- The drug’s original composition and conventional tablet protection expired decades ago.
- No material current Orange Book exclusivity or Paragraph IV litigation has been identified.
- Peganone represents the principal historical U.S. brand associated with ethotoin.
- The current market is niche, fragmented, and likely worth less than $5 million annually on a global base-case basis.
- Generic entry is legally feasible but commercially unattractive without contracted demand.
- Biosimilar competition is irrelevant because ethotoin is a small molecule.
- The main risks are product discontinuation, API availability, regulatory maintenance, and substitution by better-established anticonvulsants.
FAQs About Ethotoin
Is ethotoin still prescribed for epilepsy?
Use is extremely limited relative to newer and better-established anticonvulsants. Prescribing depends on local product availability and the clinical judgment of the treating physician.
Is Peganone the same drug as ethotoin?
Yes. Peganone is the historical brand name associated with ethotoin tablets.
Can a company launch a generic ethotoin product?
Potentially, provided it satisfies applicable regulatory, manufacturing, quality, and bioequivalence requirements. Expired patent protection is not the only barrier.
Does ethotoin have a new-drug exclusivity period?
No current new-drug, orphan, pediatric, or other meaningful regulatory exclusivity has been identified.
Is ethotoin a viable licensing target?
Only as a niche legacy-product opportunity tied to verified demand, supply continuity, or a broader portfolio. It is not an attractive standalone innovation or patent-licensing asset.
References
-
ClinicalTrials.gov. (2024). Search results for ethotoin clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (2024a). Drug safety-related labeling changes and drug discontinuations. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/
-
U.S. National Library of Medicine. (2024). DailyMed: Current medication labeling database. https://dailymed.nlm.nih.gov/
